In addition, there are several studies in preclinical and clinical settings showing that a higher frequency of multifunctional CD8+ cells that produce IFN-γ, TNF-α, CD107a, and/or IL-2 have been observed in various models of cancer immunotherapy, such as T cell therapy, antibody therapy, and vaccine therapy [41,42,43,44,45]. The gene discussed is CD8A; the disease is cancer.